Esterified estrogens
Esterified estrogens (Menest)
Esterified estrogens
(es- TER-ih-fyd ES-troh-jens)
Pregnancy Category: X Estratab Menest Neo-Estrone (Rx)

Classification: Estrogen, natural

See Also: See also Estrogens .

Action/Kinetics: This product is a mixture of sodium salts of sulfate esters of natural estrogenic substances: 75%-85% estrone sodium sulfate and 6%-15% equilin sodium sulfate. Less potent than estrone.

Uses: Replacement therapy in primary ovarian failure, following castration, or hypogonadism. Inoperable, progressing prostatic or breast carcinoma (in postmenopausal women and selected men). Moderate to severe vasomotor symptoms, atrophic vaginitis, and kraurosis vulvae due to menopause. Prophylaxis of osteoporosis (0.3 mg tablet).

How Supplied: Tablet: 0.3 mg, 0.625 mg, 1.25 mg, 2.5 mg

Dosage
?Tablets Moderate to severe vasomotor symptoms, atrophic vaginitis, or kraurosis vulvae due to menopause.
0.3-1.25 mg/day given cyclically for short-term use. Adjust dose to the lowest effective level and discontinue as soon as possible.
Hypogonadism.
2.5-7.5 mg/day in divided doses for 20 days, followed by a 10-day rest period. If menses does not occur by the end of this period of time, repeat dosage schedule. The number of courses of estrogen required to produce bleeding varies, depending on the responsiveness of the endometrium. If bleeding occurs before the end of the 10-day period, a 20-day estrogen-progestin cycle should be started with 2.5-7.5 mg/day of estrogen with a progestin added the last 5 days. If bleeding occurs before the end of this regimen, discontinue therapy and resume on day 5 of bleeding.
Primary ovarian failure, castration.
1.25 mg/day given cyclically.
Prostatic carcinoma, inoperable and progressing.
1.25-2.5 mg t.i.d. Effectiveness can be determined using phosphatase determinations and symptomatic improvement.
Breast carcinoma, inoperable and progressing, in selected men and postmenopausal women.
10 mg t.i.d. for at least 3 months.
Prophylaxis of osteoporosis.
0.3 mg daily.